The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council…

By D. Grimwade, H. Walker, G. Harrison, F. Oliver, S. Chatters, C. Harrison, K. Wheatley, A. Burnett, A. Goldstone. Blood, 2001

955 citations recorded by the source corpus.

Subfields: Hematology, Molecular Biology, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/013c10788476765ca3558d72b8e97bd5a3ad4d3d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. K. Mrózek
2. J. Byrd
3. W. van Putten
4. S. Whitman
5. R. Stone
6. C. Schiffer
7. Chantal S. Goudswaard
8. R. Dodge

Citations in the corpus

• Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. (2009, background): “adverse prognostic factors(7, 9, 25), including poor PS (Figure 2).”
• Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? (2007, background): “2-7 These cytogenetically normal (CN) patients have usually been classified in an intermediate-risk prognostic category because their CR rate, relapse risk, and survival are worse than those of adequately treated patients with such favorable aberrations as t(8;21)(q22;q22), inv(16)(p13q22)/t(16;16)(”
• Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. (2005, methodology): “A t(2;5)(p23;q35) chromosomal translocation occurs in approximately 8% of non-Hodgkin lymphomas in children and young adults and results in the chimeric fusion of NPM1 to ALK.”
• Prognostically useful gene-expression profiles in acute myeloid leukemia. (2004, neutral): “(%)* t(15;17) t(8;21) inv(16)/t(16;16) +8 +11 +21 ¡5 ¡5(q) ¡7 ¡7(q) 3q t(6;9) t(9;22) t(11q23) Complex karyotype (>3 chromosomal abnormalities) Other abnormal karyotypes Normal karyotype Not determined 18 (6) 22 (8) 19 (7) 26 (9) 7 (2) 2 (1) 3 (1) 1 (<1) 13 (5) 7 (2) 6 (2) 4 (1) 2 (1) 19 (7) 11 (4) ”
• Acute Myeloid Leukemia: Epidemiology and Etiology (2006, neutral): “Poor-risk cytogenetics have a loss of all or part of chromosome 5 or 7, translocations involving 11q23, or abnormalities of chromosome 3 [57].”
• Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). (2002, background): “Patients with t(15;17) (n 88) and t(9;22) (n 10) have subsequently been excluded from the analysis because molecularly targeted therapy with ATRA or imatinib mesylate, respectively, is now considered a standard treatment option for these AML subtypes.”
• Age and acute myeloid leukemia. (2006, neutral): “Marrow blasts, % 70 (1-99) 61 (9-99) 65 (0-99) 60 (0-96)”